Developer docs
API playgroundTry for free, no card

Search company profiles

Torreya Partners

Full company profile

uuid0009tgc

Namestring
Torreya Partners
Legal namestring
Torreya Partners
Websiteurl
torreya.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Torreya Partners is a boutique investment banking firm founded in 2007 and headquartered in New York, United States. The firm focuses exclusively on the healthcare sector, with service lines spanning pharmaceuticals, pharma licensing transactions, diagnostics, life-science tools, and medical technology. It positions itself as a specialist advisor supporting M&A, capital-raising, and licensing mandates for healthcare companies and their investors across development stages.

The firm operates as a private company with 11–50 employees and claims service coverage across the USA, United Kingdom, Canada, and France, enabling cross-border transaction support for pharmaceutical and medtech clients. Its competitive posture is built on sector specialization rather than breadth, which is the typical model for boutique healthcare advisory firms that compete on domain expertise and senior-level attention rather than balance-sheet products. Co-founder Mark Simon is listed as a co-founder and advisor, reflecting an ongoing senior role.

The business model follows the standard investment banking advisory construct: advisory fees and success-based transaction fees on M&A, licensing, and capital-raising engagements. No disclosed pricing, transaction league-table credits, or financials are available in the input data, so revenue scale and recent activity levels cannot be verified. The firm does not disclose proprietary technology, AI/ML capabilities, or productized tools; its primary deliverable is bespoke advisory service delivered by senior bankers.

Short descriptiontext

Torreya Partners is a boutique investment banking firm founded in 2007 in New York that specializes in advisory services for healthcare clients, spanning pharmaceuticals, pharma licensing, diagnostics, life-science tools, and medical technology across the USA, UK, Canada, and France.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
healthcare investment banking, pharma advisory services, biotech M&A advisory, pharma licensing advisory, life sciences capital markets
Industry2 codes
1Corporate Strategic Partnership & Ecosystem Investment Arms
CodeFSANAHAFPrimaryYes
2Sector-Focused Venture Capital (Vertical Specialists)
CodeFSANAAADPrimaryNo
NAICS code1 code
  • Securities, Commodity Contracts, and Other Financial Investments and Related Activities523
SIC code1 code
  • Security Brokers, Dealers & Flotation Companies6211
Product category
Healthcare Investment Banking
Social media profiles1 record
Cost components4 values
Personnel, Operations, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Torreya Partners is a boutique investment banking firm that provides advisory and capital-raising services focused on the healthcare and life sciences sectors, including pharmaceuticals, pharma licensing, diagnostics, life science tools, and medical technology. The firm supports clients with M&A advisory, equity and debt capital markets transactions, licensing transactions, and strategic advisory across the healthcare ecosystem.

Differentiator
Functional benefit
Problem solved
Product and service4 records
1Pharma and Biotech Investment Banking Advisory
CategoryHealthcare Investment Banking
2Pharma Licensing Advisory
CategoryPharma Licensing Advisory
3Diagnostics and Life Science Tools Advisory
CategoryHealthcare Investment Banking
4Medical Technology (Medtech) Advisory
CategoryHealthcare Investment Banking
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Middle-market healthcare investment bank with deep biopharma, medtech, and diagnostics coverage; competes with Torreya on similar mid-cap follow-on offerings and M&A mandates.

TypeDirect peer
Description

Healthcare-dedicated investment bank (now part of the broader Lazard franchise) with deep focus on biopharma, medtech, and diagnostics — directly competes with Torreya for mid- and large-cap healthcare mandates.

TypeBroad incumbent
Description

Premium global advisory firm with a sizable healthcare practice following its acquisition of Leerink — competes with Torreya for selective high-value healthcare M&A mandates.

TypeBroad incumbent
Description

Large diversified investment bank with a dedicated global healthcare group covering biopharma, diagnostics, and medtech — relevant competitor for capital markets and M&A mandates in Torreya's coverage areas.

TypeDirect peer
Description

Operating a 47-person global healthcare team with $79.1B+ raised across 440+ transactions, Stifel is a directly comparable full-service healthcare investment banking competitor covering biopharma, medtech, diagnostics, and healthtech.

TypeDirect peer
Description

Middle-market investment bank with a dedicated healthcare group covering biopharma, medtech, and diagnostics — closely comparable boutique-to-middle-market competitor to Torreya.

TypeDirect peer
Description

Healthcare-focused investment banking franchise serving biopharma, medtech, and diagnostics issuers — closely comparable in size and mid-market focus to Torreya.

TypeBroad incumbent
Description

Bulge-bracket bank with a sizable healthcare investment banking practice covering biopharma, pharma services, and life sciences tools — competes for larger healthcare mandates.

TypeDirect peer
Description

Healthcare-dedicated advisory and capital markets franchise (now part of TD Securities) with strong biopharma, diagnostics, and tools coverage — directly comparable to Torreya's positioning.

10Guggenheim Securities (Healthcare)
TypeDirect peer
Description

Bulge-adjacent healthcare investment banking group covering biopharma, life sciences tools, and medtech, frequently co-bookrunning large follow-on and IPO mandates in the same deal pool as Torreya.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Torreya Partners

Healthcare Investment Bankingtorreya.com

Torreya Partners is a boutique investment banking firm founded in 2007 in New York that specializes in advisory services for healthcare clients, spanning pharmaceuticals, pharma licensing, diagnostics, life-science tools, and medical technology across the USA, UK, Canada, and France.

What Torreya Partners does

Torreya Partners is a boutique investment banking firm founded in 2007 and headquartered in New York, United States. The firm focuses exclusively on the healthcare sector, with service lines spanning pharmaceuticals, pharma licensing transactions, diagnostics, life-science tools, and medical technology. It positions itself as a specialist advisor supporting M&A, capital-raising, and licensing mandates for healthcare companies and their investors across development stages.

The firm operates as a private company with 11–50 employees and claims service coverage across the USA, United Kingdom, Canada, and France, enabling cross-border transaction support for pharmaceutical and medtech clients. Its competitive posture is built on sector specialization rather than breadth, which is the typical model for boutique healthcare advisory firms that compete on domain expertise and senior-level attention rather than balance-sheet products. Co-founder Mark Simon is listed as a co-founder and advisor, reflecting an ongoing senior role.

The business model follows the standard investment banking advisory construct: advisory fees and success-based transaction fees on M&A, licensing, and capital-raising engagements. No disclosed pricing, transaction league-table credits, or financials are available in the input data, so revenue scale and recent activity levels cannot be verified. The firm does not disclose proprietary technology, AI/ML capabilities, or productized tools; its primary deliverable is bespoke advisory service delivered by senior bankers.

Torreya Partners firmographics

Firmographics
Name
Torreya Partners
Legal name
Torreya Partners
Website
https://torreya.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
11–50 employees
Short description
Torreya Partners is a boutique investment banking firm founded in 2007 in New York that specializes in advisory services for healthcare clients, spanning pharmaceuticals, pharma licensing, diagnostics, life-science tools, and medical technology across the USA, UK, Canada, and France.
Ownership category
akta.pro rank

Torreya Partners industry classification

Industry
Product category
Healthcare Investment Banking
NAICS
Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)
SIC
Security Brokers, Dealers & Flotation Companies (6211)
akta.pro primary industry
Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)
akta.pro secondary industry
Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

  • Healthcare investment banking
  • Pharma advisory services
  • Biotech M&A advisory
  • Pharma licensing advisory
  • Life sciences capital markets

Where Torreya Partners is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Markets served

Torreya Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D

Torreya Partners product offering

Product offering

Core offering

Torreya Partners is a boutique investment banking firm that provides advisory and capital-raising services focused on the healthcare and life sciences sectors, including pharmaceuticals, pharma licensing, diagnostics, life science tools, and medical technology. The firm supports clients with M&A advisory, equity and debt capital markets transactions, licensing transactions, and strategic advisory across the healthcare ecosystem.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharma and Biotech Investment Banking Advisory
  • Pharma Licensing Advisory
  • Diagnostics and Life Science Tools Advisory
  • Medical Technology (Medtech) Advisory

Companies that use Torreya Partners

Customer profile

Ideal customer profiles1 record

Torreya Partners technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Torreya Partners partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights3 records

Torreya Partners competitors and assessment

Company assessment

Direct peers

  • Piper Sandler (Healthcare Group): Middle-market healthcare investment bank with deep biopharma, medtech, and diagnostics coverage; competes with Torreya on similar mid-cap follow-on offerings and M&A mandates.
  • Leerink Partners: Healthcare-dedicated investment bank (now part of the broader Lazard franchise) with deep focus on biopharma, medtech, and diagnostics — directly competes with Torreya for mid- and large-cap healthcare mandates.
  • Stifel Institutional (Healthcare Investment Banking Group): Operating a 47-person global healthcare team with $79.1B+ raised across 440+ transactions, Stifel is a directly comparable full-service healthcare investment banking competitor covering biopharma, medtech, diagnostics, and healthtech.
  • Oppenheimer & Co. (Healthcare Investment Banking): Middle-market investment bank with a dedicated healthcare group covering biopharma, medtech, and diagnostics — closely comparable boutique-to-middle-market competitor to Torreya.
  • Cantor Fitzgerald (Healthcare): Healthcare-focused investment banking franchise serving biopharma, medtech, and diagnostics issuers — closely comparable in size and mid-market focus to Torreya.
  • Cowen (TD Cowen Healthcare Investment Banking): Healthcare-dedicated advisory and capital markets franchise (now part of TD Securities) with strong biopharma, diagnostics, and tools coverage — directly comparable to Torreya's positioning.
  • Guggenheim Securities (Healthcare): Bulge-adjacent healthcare investment banking group covering biopharma, life sciences tools, and medtech, frequently co-bookrunning large follow-on and IPO mandates in the same deal pool as Torreya.

Broad incumbents

  • Lazard (Healthcare Investment Banking): Premium global advisory firm with a sizable healthcare practice following its acquisition of Leerink — competes with Torreya for selective high-value healthcare M&A mandates.
  • Jefferies (Global Healthcare Investment Banking): Large diversified investment bank with a dedicated global healthcare group covering biopharma, diagnostics, and medtech — relevant competitor for capital markets and M&A mandates in Torreya's coverage areas.
  • RBC Capital Markets (Healthcare Investment Banking): Bulge-bracket bank with a sizable healthcare investment banking practice covering biopharma, pharma services, and life sciences tools — competes for larger healthcare mandates.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

Torreya Partners social profiles

Digital presence

Torreya Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Torreya Partners leadership team

Management profile

Number of profiles

Profiles1 record

Torreya Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Torreya Partners M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Torreya Partners

What does Torreya Partners do?

Torreya Partners is a boutique investment banking firm that provides advisory and capital-raising services focused on the healthcare and life sciences sectors, including pharmaceuticals, pharma licensing, diagnostics, life science tools, and medical technology. The firm supports clients with M&A advisory, equity and debt capital markets transactions, licensing transactions, and strategic advisory across the healthcare ecosystem.

Is Torreya Partners a public or private company?

Torreya Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Torreya Partners founded?

Torreya Partners was founded in 2007. It employs 11 to 50 people.

Where is Torreya Partners based?

Torreya Partners is headquartered in New York, United States, in the North America region.

Who are Torreya Partners's main competitors?

Direct peers on record are Piper Sandler (Healthcare Group), Leerink Partners, Stifel Institutional (Healthcare Investment Banking Group), Oppenheimer & Co. (Healthcare Investment Banking), Cantor Fitzgerald (Healthcare), Cowen (TD Cowen Healthcare Investment Banking) and Guggenheim Securities (Healthcare). Broad incumbents are Lazard (Healthcare Investment Banking), Jefferies (Global Healthcare Investment Banking) and RBC Capital Markets (Healthcare Investment Banking).

Does Torreya Partners have an API?

No public API is recorded for Torreya Partners.

What industry is Torreya Partners in?

Torreya Partners's product category is Healthcare Investment Banking. Its primary akta.pro industry code is FSANAHAF, Corporate Strategic Partnership & Ecosystem Investment Arms, with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523 and its SIC code is 6211.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooStifel to Acquire Torreya PartnersStifel Financial Corporation announced a definitive agreement to acquire Torreya Partners LLC, an independent M&A and private capital advisory firm specializing in the global life sciences industry. This acquisition aims to solidify Stifel's leadership position in healthcare investment banking by integrating Torreya's international team and specialized expertise. Terms of the transaction were not disclosed.PR NewswirePDL BioPharma Reports 2019 Fourth Quarter and Full Year Financial Results and Announces Plan to Dissolve the Company by Year-End 2020PDL BioPharma announced its 2019 fourth quarter and full year financial results on March 11, 2020, reporting full-year revenues of $54.8 million, with LENSAR product revenue of $30.7 million and royalty cash receipts of $79.3 million, both exceeding guidance. The company's board of directors approved a plan of complete liquidation in February 2020 and is seeking stockholder approval at the 2020 Annual Meeting to dissolve the company under Delaware law by year-end 2020, as part of a monetization strategy to return net proceeds to stockholders through asset sales and distributions.FinSMEsSaama Closes $40M Financing RoundSaama Technologies closed a $40 million financing round led by Perceptive Advisors. The company, which has raised $75 million since 2015, will use the funds to expand its AI-powered clinical trial analytics platform. Torreya Partners served as financial advisor.GlobeNewswireAeterna Zentaris Announces Strategic Review and Engagement of Financial AdvisorAeterna Zentaris announced its board formed a special committee to review strategic options and engaged Torreya as financial advisor. The review may consider licensing macimorelin outside North America, other monetization, or a sale, with no defined timeline. No further announcements are planned unless required by law.PR NewswireEnteris BioPharma Announces Positive Results from Phase 2a Clinical Trial of Ovarest® (oral leuprolide tablet) for EndometriosisEnteris BioPharma announced positive results from its Phase 2a clinical trial of Ovarest, an oral formulation of leuprolide for endometriosis treatment, demonstrating significant suppression of estradiol levels. The company plans to advance Ovarest into a Phase 2b trial to achieve Phase 3-readiness and has engaged Torreya Partners to identify growth equity and strategic partnership opportunities. Enteris also announced intentions to develop oral leuprolide for additional indications including uterine fibroid tumors and prostate cancer.